Plus THERAPEUTICS, Inc. (PSTV) intrinsic value & 10-year financials
Plus THERAPEUTICS, Inc. (PSTV) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 1.3% a year to $5.2M, with an average return on invested capital of -3488.2%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $5.2M
- Revenue growth (10-yr CAGR)
- 1.3%
- ROIC (10-yr avg)
- -3488.2%
- Free cash flow (FY2025)
- -$20.8M
PSTV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $5.2M | -$22.4M | -$0.29 | -$20.8M | -293.5% | 331.2% |
| FY2024 | $5.8M | -$13.0M | -$0.23 | -$10.7M | -252.3% | 198.1% |
| FY2023 | $4.9M | -$13.3M | -$0.42 | -$13.0M | -271.1% | 219.8% |
| FY2022 | — | -$20.3M | -$0.08 | — | — | 545.1% |
| FY2021 | — | -$13.4M | -$0.11 | — | — | -36208.7% |
| FY2020 | — | -$8.2M | — | — | — | 444.5% |
| FY2019 | — | -$10.9M | — | -$6.0M | — | -82.8% |
| FY2018 | $3.7M | -$12.6M | — | -$12.1M | -345.9% | -81.3% |
| FY2017 | $2.7M | -$22.7M | — | -$18.4M | -769.2% | -124.8% |
| FY2016 | $4.7M | -$22.0M | — | -$19.6M | -423.2% | -122.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PLUS THERAPEUTICS, INC. has demonstrated mature, steady growth, with revenue compounding at 1.3% annually over the past decade.
PLUS THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -75.6% ROIC.
PLUS THERAPEUTICS, INC. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PLUS THERAPEUTICS, INC. is modeled at 1.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2.76 per share.